Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...
The measures follow a series of fiscal and monetary policy announcements made since September to consolidate economic growth around 5% in 2024 and 2025 and soften the blow from an expected increase in ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...